(i) Hematologic toxicity-mild (ii) No grade 3 or 4 haematological toxicity, neurological or cardiotoxicity up to 90 mg/m2/wk. (iii) No hypersensitivity reactions (patients received premedication).
(i) 100% prior chemotherapy. (ii) Median dose intensity was 410 mg/m2/6 wk (range, 200 to 540 mg/m2/6 wk).
(i) No mucositis or grade III neuropathy was seen. (ii) Alopecia occurred in one.
(i) 100% prior chemotherapy (2–5 prior regimens). (ii) Partial responses were seen in four of 13 assessable patients (30%). (iii) Dose-limiting toxicity was reached at 100 mg/m2. (iv) 2-3 patients experience treatment delay. (v) Maximum-tolerated dose of 80 mg/m2.
Therapy discontinued in (i) 4 patients who had peripheral neuropathy, (ii) 1 patient due to painful fingernail beds.
(i) 100% platinum and paclitaxel resistant. (ii) Therapy was discontinued in 5 patients because of toxicity. (iii) Only 13 (1%) were modified (dose reduction or treatment delay) because of side effects.
(i) Grade 3/4 neutropenia (34%) and neutropenic fever in 2%. (ii) Nausea and vomiting and fatigue were the most frequent nonhematological side effects.
(i) Dose reduction was necessary in 25% of patients.
(i) No toxic death was recorded. (ii) Grade 2 anaemia was reported in seven patients (27%). (iii) No febrile neutropenia was observed. (iv) Grade 3 and 4 neutropenia was recorded in five (19%) and one (4%) patients. (v) Grade 3 thrombocytopenia occurred in one patient (4%).
(i) Higher anaemia (grade III + IV: 6.8% vs. 5.3%) + IV neutropenia (14.4% vs. 6.9%) decreased grade II alopecia (23.5% vs. 98.1%) and thrombocytopenia (grade III + IV: 0 vs. 2.3%).
(i) Neutropenia 30%, thrombocytopenia 8%, febrile neutropenia 0.5%. (ii) Nonhaematologic toxicity was low.
(i) Treatment was delayed in 16%, and dose reduced in 2% of cycles.
: number of patients, #: assessable for response, m: months, PI: platinum treatment free interval, RR: response rate, CR: complete remission, T: paclitaxel, C: carboplatin, PFS: progression free survival, OS: overall survival, NA: not available in paper or abstract, and NR: not yet reached. Elderly population, patient aged ≥70 years.